JPH0354661B2 - - Google Patents
Info
- Publication number
- JPH0354661B2 JPH0354661B2 JP57197859A JP19785982A JPH0354661B2 JP H0354661 B2 JPH0354661 B2 JP H0354661B2 JP 57197859 A JP57197859 A JP 57197859A JP 19785982 A JP19785982 A JP 19785982A JP H0354661 B2 JPH0354661 B2 JP H0354661B2
- Authority
- JP
- Japan
- Prior art keywords
- dimethylformamide
- hydroxyimino
- ethyl
- acetate hydrochloride
- triphenylmethylaminothiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012453 solvate Substances 0.000 claims abstract description 24
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims abstract description 5
- 239000002132 β-lactam antibiotic Substances 0.000 claims abstract description 5
- 229940124586 β-lactam antibiotics Drugs 0.000 claims abstract description 5
- NNPMQIDYDOOKNK-WYWVCWIXSA-N Cl.CN(C)C=O.CCOC(=O)C(=N/O)\C1=CSC(NC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 Chemical compound Cl.CN(C)C=O.CCOC(=O)C(=N/O)\C1=CSC(NC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 NNPMQIDYDOOKNK-WYWVCWIXSA-N 0.000 claims abstract description 3
- 229960003644 aztreonam Drugs 0.000 claims abstract description 3
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims abstract description 3
- 229960003791 cefmenoxime Drugs 0.000 claims abstract description 3
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 claims abstract description 3
- 229960004261 cefotaxime Drugs 0.000 claims abstract description 3
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims abstract description 3
- 229960001991 ceftizoxime Drugs 0.000 claims abstract description 3
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims abstract description 3
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 75
- 150000001875 compounds Chemical class 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 7
- POPNOGAIIMCRTH-MBANDDHJSA-N ethyl (2z)-2-hydroxyimino-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetate;hydrochloride Chemical compound Cl.CCOC(=O)C(=N/O)\C1=CSC(NC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 POPNOGAIIMCRTH-MBANDDHJSA-N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 claims description 3
- -1 triphenylmethylaminothiazol-4-yl Chemical group 0.000 claims description 3
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- 239000011236 particulate material Substances 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims 1
- SAVROPQJUYSBDD-UHFFFAOYSA-N formyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CO SAVROPQJUYSBDD-UHFFFAOYSA-N 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 abstract description 4
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229960001958 cefodizime Drugs 0.000 abstract description 2
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 abstract description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- BTEPYCPXBCCSDL-YHYXMXQVSA-N ethyl (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(=N/O)\C1=CSC(N)=N1 BTEPYCPXBCCSDL-YHYXMXQVSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 3
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical group NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000005646 oximino group Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 238000005866 tritylation reaction Methods 0.000 description 2
- MIHIJWOEDDPOLG-UHFFFAOYSA-N 2-methoxyiminoacetic acid Chemical compound CON=CC(O)=O MIHIJWOEDDPOLG-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8134359 | 1981-11-13 | ||
| GB8134359 | 1981-11-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58135872A JPS58135872A (ja) | 1983-08-12 |
| JPH0354661B2 true JPH0354661B2 (en, 2012) | 1991-08-20 |
Family
ID=10525889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57197859A Granted JPS58135872A (ja) | 1981-11-13 | 1982-11-12 | 新規な化合物およびその製法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US4510312A (en, 2012) |
| EP (1) | EP0088847B1 (en, 2012) |
| JP (1) | JPS58135872A (en, 2012) |
| AT (1) | ATE18219T1 (en, 2012) |
| DE (1) | DE3269474D1 (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3269474D1 (en) * | 1981-11-13 | 1986-04-03 | Glaxo Group Ltd | Thiazole derivatives and their use in the manufacture of beta-lactam antibiotics |
| US4426528A (en) * | 1982-04-01 | 1984-01-17 | Eli Lilly And Company | Purification of syn-(2-aminothiazol-4-yl)methoxyimino)acetic acid |
| CN103804395B (zh) * | 2014-01-16 | 2015-12-02 | 天津大学 | 头孢噻肟钠n,n-二甲基甲酰胺溶剂化合物及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK154939C (da) * | 1974-12-19 | 1989-06-12 | Takeda Chemical Industries Ltd | Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf |
| DE2760123C2 (de) * | 1976-01-23 | 1986-04-30 | Roussel-Uclaf, Paris | 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
| US4166115A (en) * | 1976-04-12 | 1979-08-28 | Fujisawa Pharmaceutical Co., Ltd. | Syn 7-oxoimino substituted derivatives of cephalosporanic acid |
| PH17188A (en) * | 1977-03-14 | 1984-06-14 | Fujisawa Pharmaceutical Co | New cephem and cepham compounds and their pharmaceutical compositions and method of use |
| SE439312B (sv) * | 1977-03-25 | 1985-06-10 | Roussel Uclaf | Sett att framstella nya oximderivat av 3-acetoximetyl-7-aminotiazolylacetamido cefalosporansyra |
| AR229883A1 (es) * | 1978-05-26 | 1983-12-30 | Glaxo Group Ltd | Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato |
| DE3269474D1 (en) * | 1981-11-13 | 1986-04-03 | Glaxo Group Ltd | Thiazole derivatives and their use in the manufacture of beta-lactam antibiotics |
-
1982
- 1982-11-12 DE DE8282306043T patent/DE3269474D1/de not_active Expired
- 1982-11-12 JP JP57197859A patent/JPS58135872A/ja active Granted
- 1982-11-12 AT AT82306043T patent/ATE18219T1/de not_active IP Right Cessation
- 1982-11-12 US US06/441,249 patent/US4510312A/en not_active Expired - Lifetime
- 1982-11-12 EP EP82306043A patent/EP0088847B1/en not_active Expired
-
1984
- 1984-11-19 US US06/673,095 patent/US4670552A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58135872A (ja) | 1983-08-12 |
| ATE18219T1 (de) | 1986-03-15 |
| DE3269474D1 (en) | 1986-04-03 |
| EP0088847B1 (en) | 1986-02-26 |
| US4670552A (en) | 1987-06-02 |
| US4510312A (en) | 1985-04-09 |
| EP0088847A1 (en) | 1983-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI69847B (fi) | Nytt foerfarande foer framstaellning av 7-(substituerad)amino-3-substituerad-tiometyl- 3-cefem-karboxylsyror | |
| JPH02311483A (ja) | セフトリアキソンの製造方法 | |
| CS262674B2 (en) | Process for preparing heat stable crystalline cephalosporines | |
| RU2169150C2 (ru) | Получение цефотаксима и натриевая соль цефотаксима | |
| JPS60214792A (ja) | ペナム酸エステル誘導体 | |
| JPH0354661B2 (en, 2012) | ||
| JP4022070B2 (ja) | 新規チアゾール化合物およびその製造方法 | |
| JPH069647A (ja) | 新規なセファロスポリン中間体 | |
| JP2780800B2 (ja) | セフタジジムジ塩酸塩ギ酸溶媒和物 | |
| JPS6178791A (ja) | セフエム誘導体の製造法 | |
| WO2001034611A1 (en) | Method of preparing highly pure cefpodoxime proxetil | |
| JPH0114239B2 (en, 2012) | ||
| JP4856795B2 (ja) | セファロスポリン抗生物質の製造における新規な塩 | |
| CA1236089A (en) | Ceftazidime | |
| JPH0240676B2 (en, 2012) | ||
| US4665167A (en) | Manufacture of antibiotics | |
| EP0101148B1 (en) | Thiazole derivative, process for its preparation and use in the preparation of beta-lactam antibiotics | |
| JPS6372692A (ja) | カルボン酸アミドの製造方法 | |
| JPS6322570A (ja) | １−メタンスルホニルオキシ−６−トリフルオロメチル−１ｈ−ベンゾトリアゾ−ル及びセファロスポリン誘導体の製造方法 | |
| WO2005076694A2 (en) | Improved process for the production of cefotaxime sodium | |
| JP2867438B2 (ja) | セファロスポリン化合物の製造法 | |
| BE882359A (fr) | Antibiotiques du type cephalosporine et procede de preparation | |
| KR840001378B1 (ko) | 세팔로스포린산 유도체의 제조방법 | |
| JPH0522719B2 (en, 2012) | ||
| HU195225B (en) | Process for producing crystalline monohydrate of cefem compound |